Drug or technology

Rescue Medication

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 7, 2026 · PHASE 3 TRIAL

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results reported; it describes a planned study of sacituzumab tirumotecan in early breast cancer, currently recruiting.

PreliminarySacituzumab tirumotecan NCT06966700 Breast Neoplasms

Reported

Estimated enrollment2400

Primary outcome measure 1Percentage of Participants with Pathologica…

Primary outcome measure 2Event-Free Survival (EFS), up to approximat…

AUG 7, 2026 · PHASE 3 TRIAL

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

ClinicalTrials.gov

This is a Phase 3 trial registration with no results yet posted; the study is actively recruiting and outcomes are not yet reported.

PreliminarySacituzumab tirumotecan Triple Negative Breast Neoplasms Merck Sharp & Dohme

Reported

Estimated sample size1000

Primary outcome measure 1Progression-free survival (sac-TMT versus T…

Primary outcome measure 2Overall survival (sac-TMT versus TPC), up t…